FY2026 Earnings Forecast for Exagen Issued By KeyCorp

Exagen Inc. (NASDAQ:XGN – Free Report) – Equities research analysts at KeyCorp issued their FY2026 EPS estimates for Exagen in a research report issued to clients and investors on Tuesday, November 10th. KeyCorp analyst P. Knight forecasts that the company will post earnings of ($0.71) per share for the year. The consensus estimate for Exagen’s current full-year earnings is ($0.71) per share. KeyCorp also issued estimates for Exagen’s Q4 2026 earnings at ($0.16) EPS and FY2027 earnings at ($0.49) EPS.

Exagen (NASDAQ:XGN – Get Free Report) last issued its earnings results on Tuesday, November 10th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.07). Exagen had a negative net margin of 25.14% and a negative return on equity of 125.60%. The firm had revenue of $18.42 million during the quarter, compared to analyst estimates of $18.34 million.

Other equities analysts have also recently issued research reports about the company. TD Cowen boosted their price target on Exagen from $10.00 to $11.00 and gave the stock a “buy” rating in a report on Tuesday, October 13th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Exagen in a research note on Wednesday, November 4th. B. Riley Financial started coverage on Exagen in a research report on Friday, September 11th. They issued a “buy” rating and a $12.00 target price on the stock. Canaccord Genuity Group decreased their target price on Exagen from $11.00 to $9.00 and set a “buy” rating on the stock in a research report on Wednesday, November 11th. Finally, Wall Street Zen downgraded Exagen from a “hold” rating to a “sell” rating in a research note on Saturday. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $9.88.

View Our Latest Stock Analysis on XGN

Exagen Trading Down 8.7%

Shares of XGN stock opened at $3.77 on Monday. The stock’s fifty day moving average price is $7.63 and its two-hundred day moving average price is $5.13. Exagen has a fifty-two week low of $2.59 and a fifty-two week high of $9.22. The company has a quick ratio of 3.18, a current ratio of 3.46 and a debt-to-equity ratio of 1.73.

Insiders Place Their Bets

In other Exagen news, major shareholder Jorey Chernett sold 58,068 shares of the company’s stock in a transaction dated Friday, November 13th. The stock was sold at an average price of $4.08, for a total value of $236,917.44. Following the completion of the transaction, the insider owned 2,529,436 shares of the company’s stock, valued at $10,320,098.88. This represents a 2.24% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO John Aballi sold 34,294 shares of the stock in a transaction dated Friday, October 16th. The shares were sold at an average price of $7.87, for a total value of $269,893.78. Following the completion of the transaction, the chief executive officer owned 805,540 shares of the company’s stock, valued at $6,339,599.80. This represents a 4.08% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have purchased 100,900 shares of company stock worth $568,660 and have sold 213,063 shares worth $1,084,856. Insiders own 10.40% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in XGN. Mink Brook Asset Management LLC increased its position in Exagen by 11.7% in the 3rd quarter. Mink Brook Asset Management LLC now owns 531,673 shares of the company’s stock valued at $4,323,000 after acquiring an additional 55,729 shares during the period. Marshall Wace LLP increased its position in Exagen by 28.1% in the 3rd quarter. Marshall Wace LLP now owns 392,789 shares of the company’s stock valued at $3,193,000 after acquiring an additional 86,086 shares during the period. Flputnam Investment Management Co. raised its stake in shares of Exagen by 3.8% during the third quarter. Flputnam Investment Management Co. now owns 299,828 shares of the company’s stock valued at $2,438,000 after acquiring an additional 11,018 shares during the last quarter. FourWorld Capital Management LLC raised its stake in shares of Exagen by 61.2% during the first quarter. FourWorld Capital Management LLC now owns 439,950 shares of the company’s stock valued at $1,320,000 after acquiring an additional 166,950 shares during the last quarter. Finally, GSA Capital Partners LLP bought a new position in shares of Exagen during the second quarter valued at $998,000. Institutional investors and hedge funds own 75.25% of the company’s stock.

About Exagen

(Get Free Report)

Exagen Inc. is a diagnostics company focused on testing for autoimmune and rheumatic diseases. It develops and provides blood tests intended to help physicians assess and monitor conditions such as systemic lupus erythematosus and other connective tissue diseases. The company’s AVISE test portfolio includes diagnostic and monitoring tests that use proprietary biomarkers to support clinical evaluation. Its offerings are designed to provide information that may help clinicians distinguish among autoimmune conditions and guide patient care.

Recommended Stories

Receive News & Ratings for Exagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exagen and related companies with MarketBeat.com's FREE daily email newsletter.